Clinical Evaluation of Efficacy and Safety of Dabur Vatika Nilibringhadi Gold Hair Growth Oil in Comparison to a Marketed Comparator and â??No Treatmentâ?? arm

Dabur India Limited0 个研究点目标入组 111 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1) Male and female subjectsâ?? in general good health.
•2) Subjects in the age group 18-45 years (both the ages inclusive).
•3) Subjects complaining of hair fall and damage.
•4) Subjects willing to give a written informed consent and willing to
•abide by and comply with the study protocol.
•5) Hair density of >100 and <200 hair follicle per square cm as per
•Trichoscan measurement
•6) Male & female Subjects falling under Grade 3 - Grade 6 of hair loss severity grade evaluated as per photo numerical10 point scale
•(Linear scale for assessment purpose-In use Scale).

•1) Subjects who have undergone hair growth treatment within 3 months before screening into the study.
•2) Subjects having any active scalp disease which may interfere in the study â?? dermatologistâ??s judgment.
•3) Subjects who have taken chemotherapy for cancer in the 6 months
•prior to start of the study or have a plan to do treatments during study.
•4) Subjects who have history of alcoholism, smoking, crash dieting and/ or psychiatric disorder including trichotillomania.
•5) Subjects who have had hair transplant, who have taken
•pharmaceutical product which cause hirsutism (ex. phenytoin) and
•finasteride for androgenic alopecia, under medical treatment for hair problems.
•6) A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products.
•7) Subjects on oral medications, undergoing any chemical hair salon treatment-straightening / perming / colour which will compromise the study.
•8) Subjects who are pregnant or lactating or nursing as established with medical history

发起方